Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial - Parker Institute for Cancer Immunotherapy

Research
Network
- Research Institutions
  Our academic collaborators’ seminal contributions push the field forward
- Directory
  Our constellation of renowned thinkers and partners
- Strategic Partnerships
  The right collaborators across pharma, biotech and nonprofit
- Early Career Researcher Awards
  The next generation of scientific leaders in cancer immunotherapy
News
- News Menu
  - The Latest
    Stories & Announcements
  - News Coverage
    PICI in the News
  - Podcast
    From Bench to Fireside
  - For Media
    Resources for Press
About
- Mission & Vision
  Develop breakthrough immune therapies to turn all cancers into curable diseases faster
- Leadership & Staff
  The driving force behind PICI’s research and operations
- Careers
  Join us. Change lives.
Donate